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Ghrelin Protects Spinal Cord Motoneurons Against Chronic Gluta-
mate Excitotoxicity by Inhibiting Microglial Activation
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Department of Pharmacology and Medical Research Center for Bioreaction to ROS and Biomedical Science Institute, School of Medicine, 
Kyung Hee University, Seoul 130-701, Korea
  Glutamate excitotoxicity is emerging as a contributor to degeneration of spinal cord motoneurons 
in amyotrophic lateral sclerosis (ALS). Recently, we have reported that ghrelin protects motoneurons 
against chronic glutamate excitotoxicity through the activation of extracellular signal-regulated kinase 
1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3β pathways. Previous studies 
suggest that activated microglia actively participate in the pathogenesis of ALS motoneuron dege-
neration. However, it is still unknown whether ghrelin exerts its protective effect on motoneurons via 
inhibition of microglial activation. In this study, we investigate organotypic spinal cord cultures 
(OSCCs) exposed to threohydroxyaspartate (THA), as a model of excitotoxic motoneuron degeneration, 
to determine if ghrelin prevents microglial activation. Exposure of OSCCs to THA for 3 weeks produced 
typical motoneuron death, and treatment of ghrelin significantly attenuated THA-induced motoneuron 
loss, as previously reported. Ghrelin prevented THA-induced microglial activation in the spinal cord 
and the expression of pro-inflammatory cytokines tumor necrosis factor-α and interleukin-1β. Our data 
indicate that ghrelin may act as a survival factor for motoneurons by functioning as a microglia- 
deactivating factor and suggest that ghrelin may have therapeutic potential for the treatment of ALS 
and other neurodegenerative disorders where inflammatory responses play a critical role.
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INTRODUCTION
  Amyotrophic lateral sclerosis (ALS) is a chronic, pro-
gressive neurodegenerative disease for which there is no 
cure. Individuals with ALS are characterized by the se-
lective loss of motoneurons in the spinal cord, brain stem 
and motor cortex, which results in a progressive muscle 
weakness and paralysis [1]. Despite extensive research, the 
mechanism causing motoneuron death in ALS is still most-
ly unclear; however, glutamate excitotoxicity has been im-
plicated in neurodegeneration in this disease [2]. Gluta-
mate re-uptake is diminished in synaptosomes from cerebral 
cortex and spinal cord of ALS patients [3] due to a selective 
loss of the astroglial glutamate transporter in the motor 
cortex and spinal cord [4]. These changes result in an ex-
cessive concentration of glutamate in the synaptic cleft and 
the excessive stimulation of glutamate receptors give rise 
to an increased intracellular concentration of Na
＋ and Ca
2＋, 
and then this can cause excitotoxic neuronal death [2]. 
Another common characteristic of ALS is the occurrence of 
neuroinflammatory reaction [5]. The accumulation of re-
active microglia is detected in degenerating areas of ALS 
patients and transgenic animal models [6,7]. A variety of 
noxious compounds, such as reactive oxygen species (ROS), 
reactive nitrogen species, pro-inflammatory cytokines, and 
prostaglandins, released from inappropriately activated mi-
croglia, stimulate ionotropic glutamate receptors leading to 
enhanced neuronal damage [8-10]. Considering that mino-
cycline, a semisynthetic tetracycline derivatives, is neuro-
protective against excitotoxicity by inhibiting activation 
and proliferation of microglia [11,12], the molecules target-
ing pharmacological intervention of microglial activation 
may be plausible therapeutic candidates for neuroprotec-
tive agents in ALS.
  Ghrelin, a unique peptide esterified with octanoic acid 
on Ser 3 [13], is a novel 28-amino acid hormone that is 
principally synthesized and released from Gr cells in the 
oxyntic mucosa of the stomach [14]. In addition to its potent 
stimulating effect on growth hormone (GH) release from the 
anterior pituitary gland, ghrelin induces a positive energy 
balance by increasing food intake while decreasing fat use 44 S Lee, et al
through GH-independent mechanisms [15,16]. Ghrelin also 
exerts numerous peripheral effects including direct effects 
on exocrine and endocrine pancreatic functions, carbohy-
drate metabolism, the cardiovascular system, gastric secre-
tion, stomach motility, and sleep [13]. We have demonstra-
ted that ghrelin exerts neuroprotective effects in different 
in vivo and in vitro disease models in which excitotoxicity 
has been involved, including stroke [17-19] and Parkinson’s 
disease [20]. Moreover, we recently have reported that 
ghrelin protects spinal cord motoneurons after glutamate 
excitotoxicity through the activation of extracellular sig-
nal-regulated kinase (ERK) 1/2 and phosphatidylinositol- 
3-kinase (PI3K)/Akt/glycogen synthase kinase (GSK)-3β 
pathways [21]. However, it is still unknown whether ghre-
lin exerts its protective effect in chronic glutamate-induced 
excitotoxic death of spinal cord motoneurons via inhibition 
of microglial activation. Given the accumulation of reactive 
microglia in degenerative areas is one of the cellular events 
signaling the presence of neuroinflammation in ALS [22] 
and ghrelin inhibits 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP)- and kainic acid (KA)-induced microglial ac-
tivation [20,23], these findings suggest that ghrelin may 
protect spinal cord motoneurons after glutamate excitotoxi-
city through the inhibition of microglial activation. There-
fore, in the current study, we investigated if ghrelin treat-
ment prevents microglial activation in chronic glutamate- 
induced excitotoxicity model using organotypic spinal cord 
cultures (OSCCs) exposed to an inhibitor of glutamate 
transport, threohydroxyaspartate (THA).
METHODS
Materials
  Rat ghrelin was obtained from Peptides International 
(Louisville, KT, USA). Monoclonal antibodies to mouse an-
ti-non-phosphorylated neurofilament H (SMI-32) was pur-
chased from Covance (Princeton, NJ, USA), rat anti-Mac-1 
from Chemicon (Carlsbad, CA, USA), and goat anti-tumor 
necrosis factor (TNF)-α and anti-interleukin (IL)-1β from 
R&D Systems (Minneapolis, MN, USA). All tissue culture 
reagents were obtained from Gibco/Invitrogen, and all other 
reagents were obtained from Sigma (St. Louis, MO, USA) 
unless otherwise indicated.
Organotypic rat spinal cord cultures and treatments
    OSCCs were prepared from lumbar spinal cords of 
8-day-old Sprague-Dawley rat pups (P8), as previously de-
scribed [24]. Briefly, pups were decapitated and the lumbar 
spinal cords were collected under sterile conditions and 
transferred to sterile Gey’s balanced salt solution contain-
ing glucose (6.4 mg/ml). They were transversely sectioned 
at 350 μm by using a McIIwain Tissue Chopper (Mickle 
Laboratory Engineering, Gomshall, Surrey, UK). Five or six 
complete slices were transferred to 30-mm-diameter Milli-
pore Millicell
Ⓡ-CM culture plate inserts (0.4 μm, Millipore, 
Carrightwohill, Co. Cork, Ireland). The inserts were placed 
in six-well culture plates (35-mm-diameter, Falcon, Becton- 
Dickinson, Franklin Lakes, NJ, USA), with 1 ml culture 
medium: 50% (vol/vol) minimal essential medium with 25 
mM Hepes, 25% (vol/vol) heat-inactivated horse serum and 
25% (vol/vol) Hank’s balanced salt solution supplemented 
with D-glucose (25.6 mg/ml, Sigma), 2 mM L-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco/ 
Invitrogen). Cultures were incubated at 37
oC in a 5% CO2/ 
95% air humidified incubator. Medium was changed twice 
every week. Under these conditions, cultures can be main-
tained up to 3 months with steady motoneuron survival and 
preservation of synaptic morphology. All experiments start-
ed at least 7 days after the explant procedure. Chronic glu-
tamate excitotoxicity was induced by exposure to THA (for 
1 to 3 weeks), a potent glutamate transporter inhibitor, 
which is known to produce a dose-dependent sustained ele-
vation of glutamate levels causing degeneration of moto-
neurons [25]. To determine whether ghrelin inhibits THA- 
induced motoneuron death or microglial activation in OSCCs, 
cultures were treated with ghrelin (100 nM) or vehicle at 
the same time as THA. In this study, 100 nM of ghrelin 
was chosen on the basis of our previous study that this dose 
of ghrelin exerted a potent protective effect on spinal cord 
motoneurons [21]. All experiments were performed three 
times, giving essentially identical results.
Motoneuron counts
  Motoneurons in the OSCCs were identified by SMI-32 im-
munostaining and on the basis of their morphology and size 
(＞25 μm) and their localization in the ventral horn. All 
motoneurons meeting these criteria were blindly counted 
in each spinal cord section. A minimum of 15 sections was 
counted for each experimental condition.
Immunohistochemistry
  OSCCs growing in the different experimental conditions 
were fixed with 4% paraformaldehyde (Sigma) in phos-
phate-buffered saline for 30 min at room temperature. After 
blocking with 3% normal goat serum (Vector Laboratories, 
Burlingame, CA, USA) and 1% bovine serum albumin 
(BSA) (Sigma), the sections were incubated with primary 
antibodies to SMI-32 (1：8,000), Mac-1 (1：500), TNF-α 
(1：200), or IL-1β (1：100) overnight at 4
oC. For immuno-
fluorescence, sections were incubated for 1.5 h at room tem-
perature with the appropriate secondary antibody, bio-
tinylated anti-goat IgG (1：2,000; Vector Laboratories) or 
cy3-conjugated goat anti-rat IgG (1：500, Jackson Immuno-
Research, West Grove, PA, USA). Sections were counter-
stained with DAPI and fluorescence was observed using a 
Zeiss LSM 510 Meta confocal microscope (Carl Zeiss, 
Oberkochen, Germany).
Measurement of TNF-α and IL-1β levels in culture 
medium
  The production of TNF-α and IL-1β in the OSCCs was 
determined in culture supernatants using specific ELISA 
kits (BioSource International, Inc., Camarillo, CA, USA) ac-
cording to the manufacturer’s instructions.
Statistical analysis
  Data are presented as mean±SEM. Statistical analysis 
between groups was performed using 1-way ANOVA and 
Holm-Sidak method for multiple comparisons using Sigma-
Stat for Windows Version 3.10 (Systat Software, Inc. Point 
Richmond, CA, USA). p＜0.05 was considered statistically 
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Fig. 1. Ghrelin protects spinal cord motoneurons against 
THA-induced chronic glutamate excitotoxicity. Spinal cord cultures 
were treated for 3 weeks with 100 μM THA. Either vehicle or 
ghrelin (100 nM) was added to the culture medium at the same 
time as THA. Motoneurons were identified by SMI-32 immuno-
staining and on the basis of their morphology, size and location. 
Representative micrographs of SMI-32-(＋) motoneurons in the 
ventral horn of the spinal cord are shown. Scale bar represents 
100  μm. Values are the mean±SEM of at least 15 sections per 
treatment. Each experiment was repeated three times. *p＜0.05 vs. 
control cultures; 
†p＜0.05 vs. THA-insulted, vehicle-treated cultures.
Fig. 2. Ghrelin suppresses THA-induced microglial activation in 
organotypic spinal cord cultures. Spinal cord cultures were treated 
for 1 to 3 weeks with 100 μM THA. Either vehicle or ghrelin (100 
nM) was added to the culture medium at the same time as THA. 
(A) The intensity of Mac-1 immunostaining was measured and 
presented as percent of control (mean±SEM). (B) Representative 
photomicrographs of Mac-1 immunostaining in each group are 
shown. Scale bar represents 100 μm. Each experiment was repea-
ted three times. *p＜0.05 vs. control cultures; 
†p＜0.05 vs. THA- 
insulted, vehicle-treated cultures.
RESULTS
Ghrelin inhibits spinal cord motoneuron death after 
THA-induced chronic glutamate excitotoxicity
  To investigate the effects of ghrelin on spinal cord moto-
neurons exposed to chronic glutamate-induced excitotoxi-
city, OSCCs were incubated with THA, a glutamate-uptake 
inhibitor, in the presence or absence of ghrelin. After 3- 
week exposure of OSCC to THA (100 μM), 58.8% of moto-
neurons were not viable as determined by SMI-32 immuno-
histochemistry. However, THA-induced motoneuron death 
was significantly reduced by treatment of ghrelin (100 nM) 
(Fig. 1), as we previously reported [21]. 
Ghrelin suppresses THA-induced activation of micro-
glia
  It has been reported that a neuroinflammatory response 
precedes motoneuron death caused by THA-induced gluta-
mate excitotoxicity [26]. To investigate whether the pro-
tective effect of ghrelin on spinal cord motoneurons is asso-
ciated with the inhibition of the THA-induced microglial ac-
tivation, we examined the expression of Mac-1, which is a 
specific marker for microglial activation [10]. Immunohisto-
chemical analysis showed that THA resulted in a signifi-
cant increase in the immunoreactivity of activated micro-
glia after 1 week of treatment with THA and lasted for 3 
weeks (Fig. 2). However, in THA- and ghrelin-treated cul-
tures, ventral horn Mac-1 immunoreactivities were signifi-
cantly reduced when compared with THA- and vehicle- 
treated group (Fig. 2).
Ghrelin inhibits the production of proinflammatory 
products derived from activated microglial cells
  It is well known that neuroinflammation plays important 
roles in motoneuron damage in ALS [5,9]. Pro-inflamma-
tory mediators released from activated microglia could be 
a link between neuroinflammation and excitotoxic spinal 
cord motoneuron death [5,9]. Given the fact that ghrelin 
suppressed the THA-induced microglial response, we inves-46 S Lee, et al
Fig. 3. Ghrelin inhibits the production of TNF-α from activated 
microglia in organotypic spinal cord cultures. Spinal cord cultures 
were treated for 1 to 3 weeks with 100 μM THA. Either vehicle 
or ghrelin (100 nM) was added to the culture medium at the same 
time as THA. (A) Levels of TNF-α were determined in the media 
by ELISA. Values are the mean±SEM. (B) Representative photo-
micrographs of double immunofluorescence with anti-Mac-1 and 
anti-TNF-α after 2-week exposure to THA. Scale bar represents 
100 μm. Each experiment was repeated three times. *p＜0.05 vs. 
control cultures; 
†p＜0.05 vs. THA-insulted, vehicle-treated cultures.
Fig. 4. Ghrelin inhibits the production of IL-1β from activated 
microglia in organotypic spinal cord cultures. Spinal cord cultures
were treated for 1 to 3 weeks with 100 μM THA. Either vehicle 
or ghrelin (100 nM) was added to the culture medium at the same 
time as THA. (A) Levels of IL-1β were determined in the media 
by ELISA. Values are the mean±SEM. (B) Representative photo-
micrographs of double immunofluorescence with anti-Mac-1 and 
anti-IL-1β after 2-week exposure to THA. Scale bar represents 100 
μm. Each experiment was repeated three times. *p＜0.05 vs. 
control cultures; 
†p＜0.05 vs. THA-insulted, vehicle-treated cultures.
tigated whether the release and expression of pro-inflam-
matory cytokines from activated microglial cells is inhibited 
by ghrelin treatment. Fig. 3A shows that the levels of TNF-
α released into the culture medium were increased after 
1-week exposure to THA and lasted for 3 weeks. Additional-
ly, after 2-week exposure of cultures to THA, double im-
munostaining of OSCCs with Mac-1 and TNF-α antibodies 
showed that THA resulted in a significant increase in TNF-
α immunoreactivities and most of TNF-α-positive cells co- 
localized to microglial cells (Fig. 3B). However, similar to 
the suppression of microglial activation, ghrelin treatment 
significantly inhibited the THA-induced increase of TNF-α 
(Fig. 3). We also performed ELISA analysis and immuno-
histochemistry to investigate the effect of ghrelin on THA- 
induced IL-1β release and expression in the OSCCs and 
obtained similar results (Fig. 4).
DISCUSSION
  In the present study, we show that ghrelin treatment re-
duces spinal cord motoneuron death caused by chronic glu-
tamate-induced excitotoxicity, as previously described [21]. 
The protective effect of ghrelin on motoneurons appears to 
be mediated by the inhibition of microglial activation and 
concomitant release of microglia-derived pro-inflammatory 
mediators.
  As we recently reported [21], ghrelin protects spinal cord Ghrelin Inhibits Microglial Activation 47
motoneurons from THA-induced chronic glutamate excito-
toxicity in OSCCs. It has been shown that ghrelin exerts 
its effect through the activation of its receptor GH secreta-
gogue receptor (GHS-R) 1a and activates ERK1/2 and Akt 
in motoneurons. Ghrelin-induced Akt signaling was also as-
sociated with downstream inhibition of GSK-3β in moto-
neurons [21]. Although these findings suggest a direct role 
of ghrelin on spinal cord motoneurons, there is a possibility 
that the neuroprotective effect of ghrelin may be mediated 
through the influence on non-neuronal cells, such as micro-
glia. As mediators of inflammation, reactive microgliosis is 
a considerable hallmark of ALS [6,7] and the intensity of 
microglial activation is correlated with severity of moto-
neuron damage in human ALS [9], suggesting an active in-
volvement of microglial activation in the disease. Further-
more, we recently demonstrated that ghrelin prevented mi-
croglial activation induced by MPTP and KA [20,23]. In 
agreement with these findings, we show here that ghrelin 
significantly reduces THA-induced accumulation of reactive 
microglia in the spinal cord. In that minocycline inhibits 
the activation and proliferation of microglial cells and pro-
tects motoneurons against excitotoxicity [11,12], the inhibi-
tory effect of ghrelin on microglial activation may play an 
important role in the neuroprotective effect of ghrelin in 
chronic glutamate excitotoxicity. Additionally, ghrelin may 
have a direct effect on spinal cord oligodendrocytes because 
GHS-R1a is expressed in these cells and ghrelin inhibits 
apoptotic cell death of oligodendrocytes after spinal cord in-
jury [27]. However, the precise role of ghrelin on oligoden-
drocytes remains to be determined.
  Microglia are the primary immune cells of the central 
nervous system [28]. Activated microglia are capable of pro-
ducing a variety of noxious compounds, such as ROS 
(superoxide, nitric oxide, and its derivatives), cytokines, 
and eicosanoids [8-10]. Pro-inflammatory cytokine levels, 
including TNF-α and IL-1β, are increased in the central 
nervous system of ALS patients and in mutant superoxide 
dismutase 1 transgenic mice [5,9]. These cytokines may in-
crease the susceptibility of motoneurons to glutamate tox-
icity and inhibit the function and expression of astrocytic 
glutamate transporters resulting in further neurotoxicity 
[8]. Consistent with the concept that ghrelin inhibits the 
THA-induced microglial activation, we found that ghrelin 
attenuated the expression of TNF-α and IL-1β in the spinal 
cord. This inhibitory effect of ghrelin on TNF-α and IL-1β 
may contribute to alleviating THA-induced inflammatory 
damage. Supporting evidence for this observation is that 
ghrelin shows anti-inflammatory effect in the periphery 
[29-31] and in a central hemorrhage model of brain damage 
[32]. Given the fact that the neuroprotective effect of ghre-
lin in spinal cord is associated with the inhibition of THA- 
induced microglial activation, and the subsequent increase 
in TNF-α and IL-1β, we suggest that ghrelin functions as 
a microglia-deactivating factor.
  Neuroprotective effects of ghrelin have been observed in 
numerous in vitro and in vivo models of neurodegenerative 
disorders, including Parkinson’s disease [20,33,34], stroke 
[17-19], epilepsy [23,35], and ALS [21]. It has been reported 
that both acylated and des-acyl ghrelin produce neuro-
protective effects [18,19]. Both types of ghrelin activate sim-
ilar intracellular signaling pathways, such as ERK1/2, 
PI3K/Akt, protein kinase A, and proteinase kinase C path-
ways [18]. It is interesting that des-acyl ghrelin has neuro-
protective effects independent of ghrelin receptor GHS-R1a 
[18,19]. Activation of these signaling pathways results in 
the inhibition of apoptotic cascades through the increase 
in the Bcl-2/Bax ratio, the prevention of cytochrome c re-
lease and the inhibition of caspase 3 activation [17-19,27]. 
Ghrelin prevents ischemia induced activation of p-38 and 
c-Jun NH2-terminal kinase, which activate the pro-apop-
totic events [17]. Moreover, ghrelin suppresses neuroinflam-
mation via the inhibition of microglial activation and sub-
sequent release of pro-inflammatory cytokines [20,23]. In 
addition, ghrelin promotes and protects nigrostriatal dop-
amine function via a uncoupling protein 2-dependent mi-
tochondrial mechanisms [33]. Taken together, these find-
ings provide evidence that ghrelin acts as a survival factor 
for neurons, including spinal cord motoneurons, and offer 
a new perspective on the potential role of this peptide in 
various neurodegenerative diseases.
  In summary, we found that excitotoxic death of moto-
neurons caused by THA was associated with a neuroinflam-
matory response characterized by the presence of activated 
microglia and the increased release of pro-inflammatory 
mediators, TNF-α and IL-1β, as previously described [26]. 
We provide the evidence that the neuroprotective effect of 
ghrelin is mediated by the inhibition of microglial activa-
tion and the concomitant release of pro-inflammatory cyto-
kines in the spinal cord. These findings are significant be-
cause ghrelin can function as a neuroprotective agent and 
may have therapeutic potential for the treatment of ALS 
and other neurodegenerative disorders where inflammatory 
responses play a critical role.
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